What are the recommended pharmacologic treatments for gambling disorder, including dosing, monitoring, and contraindications?

Pharmacologic Treatment for Gambling Disorder

Opioid antagonists, specifically naltrexone or nalmefene, are the only medications with sufficient evidence to recommend for gambling disorder, though they should be reserved for patients who fail psychotherapeutic interventions first. 1, 2

Evidence-Based Medication Recommendations

First-Line: Opioid Antagonists (Off-Label Use Only)

Naltrexone is the most studied medication with moderate-quality evidence showing efficacy:

• Dosing: Start 25-50 mg daily, titrate to 50-100 mg daily based on response
• Efficacy: Reduces gambling severity (SMD: -0.42) and improves quality of life (SMD: -0.50) compared to placebo 2
• Duration of trial: Minimum 8-12 weeks to assess response
• Monitoring: Baseline liver function tests; avoid in acute hepatitis or liver failure
• Side effects: Nausea (most common), headache, dizziness; higher dropout rates due to side effects (OR: 7.82) 2

Nalmefene shows slightly stronger effect sizes but less clinical experience:

• Dosing: 18-36 mg daily (based on available formulations)
• Efficacy: Larger reduction in gambling severity (SMD: -0.86) and quality of life improvement (SMD: -0.36) 2
• Tolerability: Similar side effect profile to naltrexone with comparable dropout rates (OR: 7.55) 2

Clinical Algorithm for Medication Use

1. Confirm diagnosis using DSM-5-TR criteria with severity classification

2. Initiate psychotherapy first (cognitive behavioral therapy or motivational interviewing) 3, 4

3. Consider pharmacotherapy only if:

   • Inadequate response to psychotherapy after 8-12 weeks
   • Severe symptoms causing significant functional impairment
   • Patient preference after informed discussion of limited evidence

4. If prescribing opioid antagonist:

   • Screen for opioid use (absolute contraindication if currently using opioids)
   • Check baseline liver enzymes
   • Start naltrexone 25-50 mg daily with food to minimize nausea
   • Titrate to 50-100 mg daily over 1-2 weeks
   • Reassess at 4 weeks, continue if partial response
   • Full trial requires 8-12 weeks at therapeutic dose

Medications with Insufficient Evidence

Do NOT routinely prescribe the following despite some positive studies:

• SSRIs (fluvoxamine, paroxetine, sertraline, citalopram): Inconsistent results across trials 1, 5, 6
• Topiramate: Not superior to placebo in most studies 2
• Olanzapine: Not more efficacious than placebo 2
• Lithium, valproate, other mood stabilizers: Insufficient evidence 7, 5
• Bupropion: Limited data, inconsistent results 7

Critical Caveats and Pitfalls

No FDA-approved medications exist for gambling disorder—all use is off-label 1, 4. The evidence base remains limited with:

• Small sample sizes across studies
• High placebo response rates (30-40% in most trials)
• Short follow-up periods (most studies 8-16 weeks)
• Lack of data on long-term efficacy beyond 6 months 5, 6

Common prescribing errors to avoid:

• Starting opioid antagonists without checking for current opioid use
• Using SSRIs as first-line without comorbid depression/anxiety
• Continuing ineffective medication beyond 12 weeks
• Polypharmacy without clear rationale
• Neglecting psychotherapy as primary treatment 3, 4

Assess and address comorbidities that may guide medication selection:

• Comorbid alcohol use disorder: Naltrexone has dual indication 8
• Comorbid depression: Consider SSRI, but evidence for gambling symptoms is weak 6
• Comorbid ADHD or impulse control disorders: May influence treatment response 3

Monitoring and Follow-Up

• Week 2: Assess tolerability, adjust dose if needed
• Week 4: Evaluate early response (≥25% symptom reduction suggests potential benefit)
• Week 8-12: Full efficacy assessment; discontinue if no response
• Ongoing: Monitor for return to gambling, functional outcomes, and quality of life—not just symptom scores

Discontinuation: Taper opioid antagonists over 1-2 weeks if stopping after prolonged use, though physical dependence is not typical.

The evidence remains modest at best, with effect sizes in the small-to-moderate range even for the most promising agents 2, 5. Psychotherapy remains the primary evidence-based treatment, and medication should be viewed as adjunctive for treatment-resistant cases 3, 4.